Sunshine Biopharma Inc. Cost of Revenue
Sunshine Biopharma Inc. (SBFM) reported Cost of Revenue of $6.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-13
- Sunshine Biopharma Inc. cost of revenue for the quarter ending 2026-06-30 was $6.84M, a 14.19% increase year-over-year.
- Sunshine Biopharma Inc. cost of revenue for the quarter ending 2026-03-31 was $5.91M, a 4.26% decline year-over-year.
- Sunshine Biopharma Inc. cost of revenue for the quarter ending 2025-12-31 was $5.55M, a 14.67% decline year-over-year.
- Sunshine Biopharma Inc. cost of revenue for the quarter ending 2025-09-30 was $6.34M, a 13.91% increase year-over-year.
- Sunshine Biopharma Inc. cost of revenue for fiscal 2025 was $24.05M, a 0.64% decline from fiscal 2024.
- Sunshine Biopharma Inc. cost of revenue for fiscal 2024 was $24.20M, a 53.64% increase from fiscal 2023.
- Sunshine Biopharma Inc. cost of revenue for fiscal 2023 was $15.75M, a 494.69% increase from fiscal 2022.
- Sunshine Biopharma Inc. cost of revenue for fiscal 2022 was $2.65M, a 2148.18% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.84M 10-Q · filed 2026-08-13 | $12.74M 10-Q · filed 2026-08-13 | $18.29M derived: sum of 3 quarters · filed 2026-08-13 | $24.64M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $5.91M 10-Q · filed 2026-05-13 | $11.46M derived: sum of 2 quarters · filed 2026-05-13 | $17.80M derived: sum of 3 quarters · filed 2026-05-13 | $23.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $11.89M derived: sum of 2 quarters · filed 2026-04-03 | $17.88M derived: sum of 3 quarters · filed 2026-08-13 | $24.05M 10-K · filed 2026-04-03 | ||||
| 2025-09-30 | $6.34M 10-Q · filed 2025-11-13 | $12.33M derived: sum of 2 quarters · filed 2026-08-13 | $18.50M 10-Q · filed 2025-11-13 | $25.00M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $5.99M 10-Q · filed 2026-08-13 | $12.16M 10-Q · filed 2026-08-13 | $18.66M derived: sum of 3 quarters · filed 2026-08-13 | $24.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $6.17M 10-Q · filed 2026-05-13 | $12.67M derived: sum of 2 quarters · filed 2026-05-13 | $18.24M derived: sum of 3 quarters · filed 2026-05-13 | $25.19M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $12.07M derived: sum of 2 quarters · filed 2026-04-03 | $19.02M derived: sum of 3 quarters · filed 2026-04-03 | $24.20M 10-K · filed 2026-04-03 | ||||
| 2024-09-30 | $5.57M 10-Q · filed 2025-11-13 | $12.52M derived: sum of 2 quarters · filed 2025-11-13 | $17.70M 10-Q · filed 2025-11-13 | $22.81M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $6.95M 10-Q · filed 2025-08-12 | $12.13M 10-Q · filed 2025-08-12 | $17.25M derived: sum of 3 quarters · filed 2025-08-12 | $21.21M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $5.19M 10-Q · filed 2025-05-15 | $10.30M derived: sum of 2 quarters · filed 2025-05-15 | $14.27M derived: sum of 3 quarters · filed 2025-05-15 | $17.87M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $9.08M derived: sum of 2 quarters · filed 2025-04-01 | $12.69M derived: sum of 3 quarters · filed 2025-04-01 | $15.75M 10-K · filed 2025-04-01 | ||||
| 2023-09-30 | $3.97M 10-Q · filed 2024-11-05 | $7.58M derived: sum of 2 quarters · filed 2024-11-05 | $10.64M 10-Q · filed 2024-11-05 | $13.09M derived: sum of 4 quarters · filed 2024-11-05 | ||||
| 2023-06-30 | $3.61M 10-Q/A · filed 2024-08-20 | $6.67M 10-Q/A · filed 2024-08-20 | $9.12M derived: sum of 3 quarters · filed 2024-08-20 | $9.19M derived: sum of 4 quarters · filed 2024-08-20 | ||||
| 2023-03-31 | $3.07M 10-Q · filed 2024-05-20 | $5.51M derived: sum of 2 quarters · filed 2024-05-20 | $5.58M derived: sum of 3 quarters · filed 2024-05-20 | $5.66M derived: sum of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.51M derived: sum of 2 quarters · filed 2024-03-28 | $2.59M derived: sum of 3 quarters · filed 2024-03-28 | $2.65M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $65.78K 10-Q · filed 2023-11-13 | $140.47K derived: sum of 2 quarters · filed 2023-11-13 | $200.31K 10-Q · filed 2023-11-13 | $261.60K derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $74.68K 10-Q · filed 2023-08-10 | $134.53K 10-Q · filed 2023-08-10 | $195.82K derived: sum of 3 quarters · filed 2023-08-10 | $215.32K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $59.84K 10-Q · filed 2023-05-10 | $121.13K derived: sum of 2 quarters · filed 2023-05-10 | $140.64K derived: sum of 3 quarters · filed 2023-05-10 | $159.16K derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $61.29K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-04 | $80.80K derived: sum of 2 quarters · filed 2023-04-04 | $99.31K derived: sum of 3 quarters · filed 2023-04-04 | $117.83K 10-K · filed 2023-04-04 | ||||
| 2021-09-30 | $19.51K 10-Q · filed 2022-11-07 | $38.02K derived: sum of 2 quarters · filed 2022-11-07 | $56.54K 10-Q · filed 2022-11-07 | $67.00K derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $18.52K 10-Q · filed 2022-08-03 | $37.03K 10-Q · filed 2022-08-03 | $47.50K derived: sum of 3 quarters · filed 2022-08-03 | $53.84K derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $18.52K 10-Q · filed 2022-05-06 | $28.98K derived: sum of 2 quarters · filed 2022-05-06 | $35.32K derived: sum of 3 quarters · filed 2022-05-06 | $40.48K derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $10.46K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $16.80K derived: sum of 2 quarters · filed 2022-03-21 | $21.96K derived: sum of 3 quarters · filed 2022-03-21 | $25.85K 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | $6.34K 10-Q · filed 2021-11-09 | $11.50K derived: sum of 2 quarters · filed 2021-11-09 | $15.38K 10-Q · filed 2021-11-09 | $19.57K derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $5.16K 10-Q · filed 2021-08-09 | $9.04K 10-Q · filed 2021-08-09 | $13.23K derived: sum of 3 quarters · filed 2021-08-09 | $18.52K derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2020-03-31 | $3.88K 10-Q · filed 2021-05-11 | $8.07K derived: sum of 2 quarters · filed 2021-05-11 | $13.36K derived: sum of 3 quarters · filed 2021-05-11 | $14.82K derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $4.18K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $9.48K derived: sum of 2 quarters · filed 2021-03-30 | $10.94K derived: sum of 3 quarters · filed 2021-03-30 | $11.05K 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | $5.29K 10-Q · filed 2020-11-12 | $6.75K derived: sum of 2 quarters · filed 2020-11-12 | $6.87K 10-Q · filed 2020-11-12 | $6.87K derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $1.46K 10-Q/A · filed 2020-08-31 | $1.57K 10-Q/A · filed 2020-08-31 | $1.57K derived: sum of 3 quarters · filed 2020-08-31 | $1.57K derived: sum of 4 quarters · filed 2020-08-31 | ||||
| 2019-03-31 | $112.00 10-Q · filed 2020-05-18 | $84.87K 10-Q · filed 2019-05-20 | $112.00 derived: sum of 2 quarters · filed 2020-05-18 | $112.00 derived: sum of 3 quarters · filed 2020-05-18 | $112.00 derived: sum of 4 quarters · filed 2020-05-18 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-01 | $0.00 derived: sum of 2 quarters · filed 2020-05-01 | $0.00 derived: sum of 3 quarters · filed 2020-05-01 | $0.00 10-K · filed 2020-05-01 | $391.08K 10-K · filed 2019-04-12 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-13 | $102.80K 10-Q · filed 2018-11-16 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | $293.71K 10-Q · filed 2018-11-16 | $100.82K derived: sum of 4 quarters · filed 2019-11-13 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-15 | $91.63K 10-Q · filed 2018-08-17 | $0.00 10-Q · filed 2019-08-15 | $190.91K 10-Q · filed 2018-08-17 | $100.82K derived: sum of 3 quarters · filed 2019-08-15 | $100.82K derived: sum of 4 quarters · filed 2019-08-15 | ||
| 2018-03-31 | $100.82K 10-Q · filed 2019-05-20 | $100.82K derived: sum of 2 quarters · filed 2019-05-20 | $100.82K derived: sum of 3 quarters · filed 2019-05-20 | $100.82K derived: sum of 4 quarters · filed 2019-05-20 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-12 | $0.00 derived: sum of 2 quarters · filed 2019-04-12 | $0.00 derived: sum of 3 quarters · filed 2019-04-12 | $0.00 10-K · filed 2019-04-12 | ||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-16 | $0.00 derived: sum of 2 quarters · filed 2018-11-16 | $0.00 10-Q · filed 2018-11-16 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-17 | $0.00 10-Q · filed 2018-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |